Cancer Epidemiology最新文献

{"title":"Declining early-onset lung cancer mortality in Spain: Sex-specific trends and regional variations, 1999–2022","authors":"Lucia Cayuela ,&nbsp;Anna Michela Gaeta ,&nbsp;Victoria Achaval Rodríguez ,&nbsp;Anna Annunziata ,&nbsp;Giuseppe Fiorentino ,&nbsp;Aurelio Cayuela","doi":"10.1016/j.canep.2025.102816","DOIUrl":"10.1016/j.canep.2025.102816","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer (LC) is the leading cause of cancer mortality globally, with a concerning increase in early-onset lung cancer (EO-LC), defined as cases diagnosed before age 50. This study investigates EO-LC mortality trends in Spain from 1999 to 2022, focusing on regional and gender disparities.</div></div><div><h3>Methods</h3><div>Data on LC mortality were obtained from the Spanish National Institute of Statistics, employing International Classification of Diseases codes for analysis. Joinpoint regression was utilized to estimate age-standardized mortality rates (ASMRs) and identify significant mortality trends across different Autonomous Communities (ACs).</div></div><div><h3>Results</h3><div>Total LC deaths in Spain increased; however, the proportion of EO-LC deaths significantly declined. In men, the proportion of EO-LC deaths decreased from 6.2 % to 1.6 %, while in women, it fell from 11.6 % to 3.3 %. The ASMR for EO-LC in men decreased from 8.4 per 100,000 to 1.6 per 100,000 (average annual percentage change (AAPC): −6.7 %). In women, ASMR rates fell from 1.7 per 100,000 to 1.2 per 100,000 (AAPC: −2.1 %). Notable regional declines were observed, particularly in Castile &amp; León (-8.6 %) and Madrid (-8.2 %) for men. In contrast, female mortality trends were heterogeneous, with some regions exhibiting stable rates and others showing initial increases followed by significant declines.</div></div><div><h3>Conclusions</h3><div>While our findings indicate an overall improvement in EO-LC mortality rates—particularly among men—they also reveal ongoing regional and gender disparities that require targeted intervention. The strengths and limitations of this study emphasize the need for continued surveillance and further investigations into the determinants of EO-LC mortality.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102816"},"PeriodicalIF":2.4,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of self-reported cancer diagnoses in the Korean Atomic Bomb Survivor Cohort study","authors":"Hamin Lee ,&nbsp;Jin-Wu Nam ,&nbsp;Mi Kyung Kim ,&nbsp;Inah Kim ,&nbsp;Yu-Mi Kim ,&nbsp;Boyoung Park","doi":"10.1016/j.canep.2025.102817","DOIUrl":"10.1016/j.canep.2025.102817","url":null,"abstract":"<div><h3>Background</h3><div>Owing to the short history of the National Cancer Registry, self-reported cancer history is an important source of morbidity in recently constructed cohorts or cohorts of the older population. This study aimed to evaluate the validity of the self–reported cancer history gathered through the Korean Atomic Bomb Survivor Cohort (K-ABC) study compared with the Korean Central Cancer Registry (KCCR).</div></div><div><h3>Methods</h3><div>Among the K-ABC participants recruited from 2020 to 2024, self-reported cancer history from 1756 participants was linked to the KCCR. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and kappa coefficient were estimated for each cancer site.</div></div><div><h3>Results</h3><div>Among 181 participants with a minimum of one record in the KCCR, 164 reported a history of cancer. Overall cancers and each cancer site showed high sensitivity, PPV, and kappa values of &gt; 80 %, &gt; 66 %, and &gt; 0.73, respectively, except for cervical and lung cancers, which showed sensitivities of &lt; 50 % and kappa values of 0.33 and 0.59, respectively. High specificity and NPV (≥99 %) were observed for all cancer sites.</div></div><div><h3>Conclusions</h3><div>The validity of the self-reported cancer history of the K-ABC showed a relatively high level of agreement with the KCCR records. These findings indicate that self-reported cancer information from the K-ABC study is valid for all sexes and ages but needs consideration when used for evaluating cervical and lung cancer.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102817"},"PeriodicalIF":2.4,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult glioblastoma in England: Incidence, treatment, and outcomes with novel population-based strata","authors":"Kerlann Le Calvez ,&nbsp;Radvile Mauricaite ,&nbsp;Peter Treasure ,&nbsp;Thomas C. Booth ,&nbsp;Stephen J. Price ,&nbsp;Andrew Brodbelt ,&nbsp;Jonathan J. Gregory ,&nbsp;Seema Dadhania ,&nbsp;Lillie Pakzad-Shahabi ,&nbsp;Maureen Dumba ,&nbsp;Ingela Oberg ,&nbsp;Sally Vernon ,&nbsp;Jawad Basharat ,&nbsp;Matt Williams","doi":"10.1016/j.canep.2025.102811","DOIUrl":"10.1016/j.canep.2025.102811","url":null,"abstract":"<div><h3>Introduction</h3><div>Malignant brain tumours are the leading cause of cancer death in the under 40’s and they have the highest average-years of life lost. England has a long-running system for national cancer data collection. In this work we present data on incidence, treatment and survival in all adult glioblastoma patients in England diagnosed between 2013 and 2018.</div></div><div><h3>Methods</h3><div>GlioCova uses a linked pseudo-anonymised data set of all adult patients in England diagnosed with a primary brain tumour between 2013 and 2018. We identified all patients with a glioblastoma (GBM) based on ICD-10 diagnosis and tumour morphology.</div></div><div><h3>Results</h3><div>In the 6-year period of the study (2013–2018 inclusive), 15,181 patients were diagnosed with a GBM in England. The national age-standardised incidence was 4.98 adult glioblastoma patients per 100,000 per year, with men having a higher incidence than women (6.3 and 3.8 respectively). Overall, 79 % of patients received treatment (76 % female vs. 81 % male, p = 0.22), with younger patients more likely to be treated than older patients. Median overall survival was 16 months in those receiving aggressive treatment, but 7 months in the whole cohort. 21 % of patients received no treatment, and 17 % of patients underwent surgery or biopsy alone.</div></div><div><h3>Conclusion</h3><div>Age-adjusted incidence of GBM is stable, although absolute numbers are rising, and prognosis remains poor. Only 29 % of patients receive aggressive multi-modality treatment, and we suggest that taking a population-level approach to GBM reveals significant areas for improvement.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102811"},"PeriodicalIF":2.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort","authors":"Christelle Cantrelle ,&nbsp;Aurélien Belot ,&nbsp;Alain Monnereau ,&nbsp;Fontanet Bijou ,&nbsp;Cédric Rossi ,&nbsp;Hadia Khebbeb Hafirassou ,&nbsp;Ludovic Fouillet ,&nbsp;Pierre Soubeyran ,&nbsp;Hervé Ghesquières ,&nbsp;Loic Ysebaert ,&nbsp;Sandra Le Guyader Peyrou ,&nbsp;Angéline Galvin","doi":"10.1016/j.canep.2025.102812","DOIUrl":"10.1016/j.canep.2025.102812","url":null,"abstract":"<div><h3>Introduction</h3><div>Over a half of diffuse large B-cell lymphoma (DLBCL) cases are diagnosed in adults aged 65 years and older. Older adults are a heterogeneous group, and few studies reported differences in care management and survival in the oldest old. We aimed to describe characteristics, care management, and survival of older adults aged 60 and over included in the REal-world dAta in LYmphoma and Survival in Adults (REALYSA) study.</div></div><div><h3>Materials</h3><div>and methods: Patients newly diagnosed with DLBCL, aged over 60 years, included in REALYSA cohort between 2018/11 and 2021/12 and receiving therapy (RCHOP/miniRCHOP/Other) were included. Sociodemographic, living area and clinical characteristics, as well as the type of care center and pathway during the first year after diagnosis were described by age (60–69 y/70–79 y/≥80 y). Survival was described using Kaplan-Meier curves, the Cox model for adjusted survival, and net survival (Pohar-Perme estimator).</div></div><div><h3>Results</h3><div>A total of 560 DLBCL patients with a median age at diagnosis of 72 years (IQR=67–77) were included. R-CHOP was the main curative treatment in patients aged 60–79, and R-miniCHOP in the oldest old. More than half of the patients were male, married or in a relationship, living in urban and low deprived area. With increasing age, the proportion of patients with performance status 0–1 or no Charlson comorbidity at diagnosis decreased. Two thirds of patients were diagnosed at advanced stage with comparable trends between age groups. However, the oldest patients were more likely to have high-risk disease and geriatric frailty at diagnosis. One-year net survival, in contrast to OS (91 %vs 95 % and 75 % for each age group), showed no significant reduction in survival for 80 + (93 %, 100 % and 87 % for each age group).</div></div><div><h3>Conclusion</h3><div>As the fastest-growing age group in developed countries, the oldest old require a special attention and further work on this population is needed.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102812"},"PeriodicalIF":2.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019–2020: A nationwide study","authors":"J.W. Ankersmid-Matos Miguel ,&nbsp;N.L. van Veen ,&nbsp;W. Jacobs ,&nbsp;R.A.M. Damhuis ,&nbsp;C.F. van Uden-Kraan ,&nbsp;E.M.W. van de Garde ,&nbsp;on behalf of the Santeon VBHC Lung Cancer Research Group","doi":"10.1016/j.canep.2025.102809","DOIUrl":"10.1016/j.canep.2025.102809","url":null,"abstract":"<div><h3>Background</h3><div>The treatment landscape for patients with metastatic non-small cell lung cancer (mNSCLC) is rapidly evolving as new therapies are continually introduced. This study aimed to provide a contemporary overview of how patients diagnosed with mNSCLC in the Netherlands are treated in routine clinical practice, how applied systemic treatments are tolerated and with which overall survival (OS).</div></div><div><h3>Methods</h3><div>This nationwide retrospective study utilised data from the Netherlands Cancer Registry (NCR) complemented by electronic health records data of patients diagnosed with stage IV non-oncogenic mNSCLC in the years 2019–2020. First-line (1 L) treatments and corresponding overall survival (OS) were identified and compared across hospital types (academic, teaching, general), along with a multivariable analysis of 1 L treatment, patient, and tumour characteristics. In a subset of seven teaching hospitals, dose adjustments, early discontinuations and follow-up treatments were also assessed together with ESMO guideline adherence based on ECOG scores and levels of PD-L1 tumour expression.</div></div><div><h3>Results</h3><div>The total sample comprised 9511 patients (56 % male and mean age 68 years) of which 4485 (47 %) received best supportive care (BSC) only. The most frequently applied 1 L systemic treatment was chemo-immunotherapy with 51 % one-year survival. Starting any 1 L systemic treatment was more frequent among patients with younger age, better performance status, PD-L1 &gt; 50 %, and those with their diagnosis established in an academic hospital. Chemotherapy was discontinued early (&lt;4 cycles) in 46 % of patients with 1 L chemotherapy and 34 % of patients with chemo-immunotherapy. Guideline adherence was highest in patients with ECOG1 and PD-L1 1–49 % (76 %) and lowest in the ECOG &gt; = 2 and PD-L1 1–49 % group (30 %).</div></div><div><h3>Conclusions</h3><div>Best supportive care over systemic treatment and chemotherapy treatment modifications are common in patients with mNSCLC. Presenting information to patients about these outcomes can support shared-decision making.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102809"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes medications and pancreatic cancer risk: A population-based cohort study","authors":"Yixian Chen ,&nbsp;Parveen Bhatti ,&nbsp;Trevor Dummer ,&nbsp;Rachel A. Murphy","doi":"10.1016/j.canep.2025.102808","DOIUrl":"10.1016/j.canep.2025.102808","url":null,"abstract":"<div><h3>Background</h3><div>Studies of the relationship between diabetes medications and pancreatic cancer risk have produced inconclusive results. We aimed to examine associations between classes, subclasses, and individual diabetes medications with pancreatic cancer risk in a population-based retrospective cohort study.</div></div><div><h3>Methods</h3><div>Among British Columbians aged ≥ 35 (1996–2019), prescriptions for diabetes medications were categorised by ever/never use, cumulative duration, and dose. Time-varying Cox proportional hazards models adjusted for demographics were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for associations between new diabetes medication use and pancreatic cancer. Confounding by indication was explored using active comparator analysis of ever/never associations relative to pioglitazone use.</div></div><div><h3>Results</h3><div>The cohort consisted of 3,118,538 people (52,088,644 person-years), 7,540 of whom were diagnosed with pancreatic cancer. For every one-year increase in cumulative dose, diabetes medications in the insulin secretagogue class, and glyburide; an individual medication within the class, were associated with 2 % (HR=1.02, 95 % CI=1.02–1.03) and 3 % (HR=1.03, 95 % CI=1.02–1.05) increased risk of pancreatic cancer. For every one-year increase in cumulative dose, medications within the insulins and analogues class and insulin subclasses (basal and bolus insulins) were linked to a 4 % higher risk (HR=1.04, 95 % CI=1.03–1.05) of pancreatic cancer. In the active comparator analysis, elevated risk for basal insulins (HR=1.49, 95 % CI=0.33–6.63) was observed, consistent with the main analysis, although the risk was not statistically significant.</div></div><div><h3>Conclusion</h3><div>Basal insulins may be associated with higher pancreatic cancer risk. Although confirmatory studies are needed, this finding may be informative for prescribing practices for high-risk populations with diabetes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102808"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary to Oliveros et al., Cancer Epidemiol 2025;96:102784","authors":"Esther de Vries ,&nbsp;Nelson Arias-Ortiz ,&nbsp;Marion Piñeros","doi":"10.1016/j.canep.2025.102813","DOIUrl":"10.1016/j.canep.2025.102813","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102813"},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival analysis in adult Burkitt Lymphoma in Colombia according to HIV status","authors":"Juan Felipe Combariza ,&nbsp;Harold Pineda ,&nbsp;Laura Díaz","doi":"10.1016/j.canep.2025.102805","DOIUrl":"10.1016/j.canep.2025.102805","url":null,"abstract":"<div><h3>Introduction</h3><div>Burkitt lymphoma is a highly aggressive Non-Hodgkin Lymphoma, is considered a rare tumor, accounts for only 1–2 % of adult lymphomas in North America. The two-year Overall survival rates was reported between 67 % and 84 %. Statistics from developing countries comes mainly from children studies in Africa where Burkitt Lymphoma is endemic. In Latin American countries, information about survival in adult population is scarce with limited number of patients and poor survival outcomes mainly in HIV associated Burkitt Lymphoma. The aim of this study is to evaluate survival in adults’ patients with BL, and HIV status in a Colombian cohort.</div></div><div><h3>Materials and methods</h3><div>A retrospective cohort study was conducted to determine the demographic characteristics, treatment, and survival of adult Burkitt Lymphoma patients in Colombia. The study included adult patients diagnosed with Burkitt Lymphoma between 2004 and 2023, and calculate Overall survival and progression free survival of the population, and according to HIV status</div></div><div><h3>Results</h3><div>83 patients were included for analysis with 49 (59 %) patients with a sporadic variant and 34 (41 %) with an immunodeficiency-associated variant. The median age at diagnosis was 40 years, IQR (30 – 52), The 36-months OS was 49.9 % (95 % CI; 39.6 – 62.9 %)), and 36-months PFS was 51.5 % (95 % CI¸41.5 – 64.5). For HIV patients 36-months OS was 41 % (95 % CI; 26.7 – 62.7 %) and 59.2 % (95 % CI; 45.8 – 76.6 %) HIV negative HR 1.72 (95 % CI; 0.93 – 1.19 (p = 0.08).</div></div><div><h3>Conclusion</h3><div>this study suggests an OS survival inferior than reported for developed countries with inferior survival rates in HIV patients</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102805"},"PeriodicalIF":2.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of the COVID-19 pandemic on the use of systemic therapy for patients diagnosed with cancer in England: A population-based study with a focus on breast and lung cancer","authors":"Laura Webster ,&nbsp;Sarah Lawton ,&nbsp;Katherine Thackray ,&nbsp;Matthew Barclay ,&nbsp;Martine Bomb ,&nbsp;Georgios Lyratzopoulos ,&nbsp;David Dodwell ,&nbsp;Emma Kipps","doi":"10.1016/j.canep.2025.102806","DOIUrl":"10.1016/j.canep.2025.102806","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic caused substantial disruption to the delivery of cancer treatment. We aimed to describe the impact on the use of systemic anti-cancer therapy (SACT) in England with a focus on the treatment of breast and lung cancer.</div></div><div><h3>Methods</h3><div>We identified patients newly diagnosed with cancer between January 2019 and December 2020 from the National Cancer Registration Dataset. We describe the changes in the number and stage distribution of patients, and the proportion receiving SACT within 12 months of diagnosis of breast and lung cancer.</div></div><div><h3>Results</h3><div>An estimated 7704 fewer breast cancer patients and 2286 fewer lung cancer patients were newly diagnosed in 2020 compared to 2019. This was concordant with a reduction in the number of SACT administrations delivered within 12 months post-diagnosis. However, an increased proportion received SACT from April to December 2020 for patients diagnosed with breast cancer, which was not seen for lung cancer patients.</div></div><div><h3>Conclusions</h3><div>Changes in the delivery of SACT were largely driven by a reduction in the number of patients who were diagnosed with cancer in 2020. An increased proportion of breast cancer patients treated with SACT likely reflects the increased proportion of patients who were diagnosed with stage III and stage IV disease.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102806"},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and cross-country inequalities in the global, regional, and national burden of gallbladder and biliary tract cancer from 1990 to 2021, along with the predictions for 2035","authors":"Wen Bao ,&nbsp;Lichun Qiao ,&nbsp;Miaoqian Li ,&nbsp;Guoming Shi ,&nbsp;Liang Liu","doi":"10.1016/j.canep.2025.102802","DOIUrl":"10.1016/j.canep.2025.102802","url":null,"abstract":"<div><h3>Background</h3><div>The global burden of gallbladder and biliary tract cancer (GBTC) is on the rise.</div></div><div><h3>Methods</h3><div>The incidence, mortality, and disability-adjusted life years (DALYs) of GBTC from 1990 to 2021 were obtained from the Global Burden of Diseases Study (GBD) 2021. The Bayesian Age-Period-Cohort (BAPC) model was also employed to project disease trends for the next 15 years.</div></div><div><h3>Results</h3><div>In 2021, new GBTC cases observed globally amounted to 216,768, with 171,961 mortality and 3732,121 DALYs. From 1990–2021, a notable surge was recorded in the incidence of GBTC by 101 %, mortality by 74.26 %, and DALYs by 60.45 %. Regions with superior Socio-Demographic Index (SDI) reflected elevated incidence and mortality rates. However, a significant decrease was noticed in the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR). Despite a reduction in health disparities among countries, differences remain. Prognostications predict a continual decline in global ASIR and ASMR through 2035.</div></div><div><h3>Conclusions</h3><div>The study found that the burden of GBTC in incidences, mortalities, and DALYs has been on the rise, with some correlation with socio-economic development.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"96 ","pages":"Article 102802"},"PeriodicalIF":2.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}